Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 11:06 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2065–2088 of 2,293 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cardiac Ischemia Clear all

Conditions: Diabetes, Hypertension, Dyslipidemia, Coronary Arteriosclerosis
Interventions: Behavioral counseling and peer support, Interactive Education, Role modeling, Pharmacologic case management; Behavioral · Procedure
Lead sponsor: Providence VA Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Coronary Artery Disease, Myocardial Ischemia
Interventions: AngioSculpt Scoring Balloon Catheter; Device
Lead sponsor: AngioScore, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetes, Dyslipidemia, Hypertension, Coronary Atherosclerosis
Interventions: Counseling, Interactive Education, Group Support, Pharmacologic case management; Behavioral · Procedure
Lead sponsor: Providence VA Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Peripheral Arterial Disease, Angina
Interventions: Ranolazine, Placebo; Drug
Lead sponsor: Colorado Prevention Center; Other
Eligibility: 40 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 3
States / cities: Aurora, Colorado • Denver, Colorado

Conditions: Stable Angina, Metabolic Syndrome
Interventions: Ranolazine, Placebo; Drug · Other
Lead sponsor: University of Florida; Other
Eligibility: 30 Years to 75 Years · Female only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Coronary Artery Disease
Interventions: Adenosine; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Arteriosclerosis, Coronary Artery Disease, Myocardial Ischemia, Coronary Disease
Interventions: CrossBoss Catheter, Antegrade Wire Escalation Strategy; Procedure
Lead sponsor: North Texas Veterans Healthcare System; Federal
Eligibility: 18 Years and older
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 11
States / cities: Boston, Massachusetts • Detroit, Michigan • Minneapolis, Minnesota + 8 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Not listed
Lead sponsor: Oregon Research Institute; Other
Eligibility: 40 Years to 75 Years · Female only
Enrollment: 227 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Eugene, Oregon

Conditions: Atherosclerosis, Cardiovascular Diseases, Heart Diseases, Carotid Artery Diseases, Myocardial Ischemia
Interventions: Not listed
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1990 – 1995
U.S. locations: 1
States / cities: New York, New York

Conditions: Ischemia
Interventions: CT and stress test; Procedure
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 5
States / cities: Overland Park, Kansas • New York, New York • Columbus, Ohio + 2 more

Conditions: Chronic Total Occlusion of Coronary Artery
Interventions: DyeVert System; Device
Lead sponsor: Minneapolis Heart Institute Foundation; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 3
States / cities: Minneapolis, Minnesota

Conditions: Atrial Fibrillation, Ischemic Stroke, Peripheral Thromboembolism
Interventions: AMPLATZER Cardiac Plug; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 18
States / cities: Los Angeles, California • Aurora, Colorado • Littleton, Colorado + 13 more

Conditions: Normal Healthy Volunteers Without Chronic Medical Conditions, Coronary Artery Disease, Cardiac Risk Factors, Myocardial Infarction
Interventions: Slow Infusion of Rubidium-82; Drug
Lead sponsor: Ochsner Health System; Other
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Coronary Artery Disease, Angina Pectoris, Chest Pain, Cardiovascular Diseases, Coronary Heart Disease, CAD, CVD, CHD
Interventions: Corus CAD (ASGES); Diagnostic Test
Lead sponsor: CardioDx; Industry
Eligibility: 45 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Coronary Artery Disease
Interventions: CorMatrix extra cellular matrix (ECM); Device
Lead sponsor: Inova Health Care Services; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Falls Church, Virginia

Conditions: Cardiovascular Disease and Lipoprotein(a)
Interventions: Pelacarsen (TQJ230); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 5,700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 120
States / cities: Andalusia, Alabama • Huntsville, Alabama • Mobile, Alabama + 101 more

Conditions: Cardiovascular Disease
Interventions: Dalcetrapib, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 936 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 41
States / cities: Los Angeles, California • Torrance, California • Boulder, Colorado + 36 more

Conditions: Ischemia
Interventions: Communication with exercise therapist, mHealth-CR, Wearable activity monitoring device; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Acute Coronary Syndrome, Chest Pain, Risk Reduction
Interventions: modified HEART score and/or Emergency Department Assessment of Chest pain Risk Score (EDACS); Other
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years and older
Enrollment: 13,419 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 12
States / cities: Antioch, California • Fremont, California • Oakland, California + 8 more

Conditions: Cardiac Disease
Interventions: Not listed
Lead sponsor: Methodist Health System; Other
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Acute Coronary Syndrome
Interventions: Not listed
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Ischemic Heart Disease, Hopelessness, Physical Activity, Motivation, Social Support, Covid19
Interventions: Motivational social support from nurse, Motivational social support from nurse with additional support from significant other, Attention control; Behavioral
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Grand Rapids, Michigan

Conditions: Cardiovascular Disease, Cardiomyopathy, Heart Disease, Myocardial Disease, Myocardial Ischemia
Interventions: Atorvastatin Calcium; Drug
Lead sponsor: Philip Binkley; Other
Eligibility: 18 Years to 85 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Cancer, Coronary Artery Disease
Interventions: PET-MR imaging on Biograph mMR scanner, MR-only imaging on Biograph mMR scanner, MR imaging on the Siemens Vida 3T MR scanner; Other
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2040
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

Combined Behavioral and Pharmacological Intervention for Cardiovascular Risk Reduction in Diabetic Patients

AngioSculpt® Coronary Bifurcation Study

Strategies to Maintain Cardiac Risk Control After Discharge From Cardiovascular Risk Reduction Clinic

Ranolazine Versus Placebo Effects on Exercise Tolerance in Patients With Heart Disease and Peripheral Arterial Disease

Impact of Ranolazine in Blood Markers in Women With Angina and Metabolic Syndrome

Effect of Ticagrelor vs. Dipyridamole on Adenosine Uptake

Comparison of a CrossBoss First Versus Standard Wire Escalation Strategy for Crossing Coronary Chronic Total Occlusion: the "CrossBoss First" Trial

Enhancing Support for Women With Type 2 Diabetes: Follow-Up

Postprandial Lipoproteins and Atherosclerosis

Dual Energy CT for Ischemia Determination Compared to "Gold Standard" Non-Invasive and Invasive Techniques

REduction of Contrast Via DyeVert Used in CTO Procedures

AMPLATZER Cardiac Plug Clinical Trial

3D PET Myocardial Blood Flow and Rb82 Infusion Profiles

Effect of Exercise Stress Testing on Peripheral Gene Expression Using Corus CAD (or ASGES) Diagnostic Test

CorMatrix ECM Study: To Identify Inflammatory Markers Following CABG With/Without ECM

An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

A Study of the Effect of Dalcetrapib on Artherosclerotic Disease in Patients With Coronary Artery Disease

mHealth-CArdiac REhabilitation for INOCA

Standardizing Emergency Work-ups Around Risk Data

Triple Antithrombotic Therapy in Cardiac Patients Requiring Revascularization

Platelet Reactivity After CABG

Reducing Hopelessness Through Improved Physical Activity in Adults With Heart Disease: With COVID-19 Considerations

Statin Therapy for Ischemic and Nonischemic Cardiomyopathy

Calibration of MR and PET-MR Imaging Protocols at RIC